UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009976
Receipt number R000011686
Scientific Title Pharmacokinetics of salazosulfapiridine with crucumin and blood miRNA-328
Date of disclosure of the study information 2013/02/22
Last modified on 2014/10/14 15:24:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pharmacokinetics of salazosulfapiridine with crucumin and blood miRNA-328

Acronym

Pharmacokinetics of salazosulfapiridine with crucumin

Scientific Title

Pharmacokinetics of salazosulfapiridine with crucumin and blood miRNA-328

Scientific Title:Acronym

Pharmacokinetics of salazosulfapiridine with crucumin

Region

Japan


Condition

Condition

healthy male and female

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

1) to evaluate blood miRNA levels as biomarker for BCRP function
2) to assess the relationship between change in miR-328 expression and BCRP function

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

pharmacokinetics of salazosulfapiridine, blood miR-328 levels

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Food

Interventions/Control_1

salazosulfapiridine, wash out, crucumin, salazosulfapiridine

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

45 years-old >=

Gender

Male and Female

Key inclusion criteria

The investigators must ensure that all subjects being considered meet the ollowing
inclusion criteria:
1) Japanese healthy male or female who is capable to understand and sign the informed consent
2) 20-45 years of age
3) BMI 17.6-26.4
4) good health as determined by physical examination, vital signs and laboratory tests.

Key exclusion criteria

The investigators must ensure that all subjects being considered meet the ollowing
exclusion criteria or conditions:
1) history of allergy to any drugs
2) medical attention within 2 months prior to participation
3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation
4) donation of 400 mL or more of blood within 12 weeks prior to participation
5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity
6) history of drug abuse
7) alcohol abuse.

Target sample size

45


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shin Irie

Organization

LTA

Division name

Sugioka Memorial Hospital

Zip code


Address

3-6-1, Kashiiteruha, Higashi-ku, Fukuoka

TEL

092-662-3608

Email

shin-irie@lta-med.com


Public contact

Name of contact person

1st name
Middle name
Last name Noritomo Izumi

Organization

LTA

Division name

Hakata Clinic

Zip code


Address

Random Square 5 - 7 FL, 6-18, Tenyamachi, Hakata-ku, Fukuoka

TEL

092-283-7701

Homepage URL


Email

noritomo-izumi@lta-med.com


Sponsor or person

Institute

Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University

Institute

Department

Personal name



Funding Source

Organization

Japanese Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 02 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 02 Month 15 Day

Date of IRB


Anticipated trial start date

2013 Year 02 Month 22 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 02 Month 06 Day

Last modified on

2014 Year 10 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011686


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name